P3 Health Partners Inc PIII.OQ PIII.O is expected to show a fall in quarterly revenue when it reports results on August 14 for the period ending June 30 2025
The Chicago Illinois-based company is expected to report a 5.5% decrease in revenue to $358.223 million from $379.16 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for P3 Health Partners Inc is for a loss of $4.74 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for P3 Health Partners Inc is $15.00, about 56% above its last closing price of $6.60
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -7.76 | -8.91 | -6.28 | Beat | 29.6 |
Dec. 31 2025 | -4.10 | -19.50 | Missed | -375.6 | |
Sep. 30 2024 | -1.89 | -1.87 | -14.50 | Missed | -673.3 |
Jun. 30 2024 | -3.47 | -2.50 | -4.50 | Missed | -80 |
Mar. 31 2024 | -5.64 | -5.33 | -8.00 | Missed | -50 |
Dec. 31 2023 | -9.50 | -5.50 | -11.00 | Missed | -100 |
Sep. 30 2023 | -14.55 | -11.00 | -6.00 | Beat | 45.5 |
Jun. 30 2023 | -7.11 | -6.50 | -4.50 | Beat | 30.8 |
This summary was machine generated August 12 at 20:04 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)